Octreotide prolonged-release - Ambrilia Biopharma

Drug Profile

Octreotide prolonged-release - Ambrilia Biopharma

Alternative Names: C2L; C2L-OCT-01 PR

Latest Information Update: 09 Jul 2013

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acromegaly

Most Recent Events

  • 07 Aug 2013 Biomarkers information updated
  • 09 Jul 2013 Discontinued - Phase-III for Acromegaly in Europe prior to 9 July 2013 (IM)
  • 24 Jan 2012 Ascent Pharmahealth has been acquired by Watson Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top